AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01041989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
Study NCT01041989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of vascular risk factors
Description: Monitoring and maintenance of metabolic and vascular risk factors
Study NCT01861977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
Study NCT01861977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Workshop
Description: Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
Study NCT00913523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental - Tampon with GML
Description: Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
Study NCT00913523 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control - Tampons without GML
Description: There is no intervention associated with these arms - they are sham controls.
Study NCT02932553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BVS+OMT
Description: bioresorbable vascular scaffold implantation plus optimal medical treatment
Study NCT01457274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation depth
Description: The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (\<60) than those in the light sedation group (BIS 70-80).
Study NCT01457274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation depth
Description: The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (\<60) than those in the light sedation group (BIS 70-80).
Study NCT01416935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Amiodarone
Description: This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
Study NCT00307164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NucleomaxX
Description: 36 g sachet taken orally three times daily
Study NCT00307164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NucleomaxX placebo
Description: 36 g placebo sachet taken orally three times daily
Study NCT00947232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
Study NCT00947232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
Study NCT00583271 — intervention group
Intervention type: DRUG
Intervention: triamcinolone
Description: 80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
Study NCT00583271 — intervention group
Intervention type: DRUG
Intervention: 98% dehydrated alcohol
Description: 10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
Study NCT03042364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pipelle de Cornier
Description: RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
Study NCT02871583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lichtenstein
Description: tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
Study NCT02871583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kugel
Description: preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
Study NCT01547598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost ophthalmic solution 0.004%
Description: Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
Study NCT03704506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxil capsule
Description: amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
Study NCT03704506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reyanning mixture simulator
Description: Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
Study NCT01547598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost 0.004% / timolol 0.5% combination ophthalmic solution
Description: DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
Study NCT01547598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost ophthalmic solution 0.01%
Description: LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
Study NCT01496365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565 tablet
Description: 5mg and 10mg tablets
Study NCT01496365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin capsule
Description: 75mg and 150mg over-encapsulated
Study NCT01496365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Study NCT01496365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo capsule
Study NCT00565266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide inhalation powder 18 mcg once daily
Study NCT00565266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: salmeterol xinafoate inhalation powder 50 mcg twice daily
Study NCT00565266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
Study NCT00777634 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
Study NCT02480699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recurring blood sample
Study NCT02480699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary survey
Description: A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
Study NCT02503098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Record adaptive smartphone application
Study NCT02503098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recovery Record standard smartphone application
Study NCT04719299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell-Play-Do
Description: Using smart phone application
Study NCT04719299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tell-Show-Do
Description: Using traditional behavior management technique
Study NCT05194670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enhanced depth of focus IOL
Description: Acunex Vario AN6V, enhanced depth of focus IOL
Study NCT05194670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monofocal IOL
Description: Acunex AN6, monofocal IOL
Study NCT02924597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero ischemia robot-assisted laparoscopic RFA assisted TE
Study NCT02924597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zero ischemia robot-assisted laparoscopic partial nephrectomy
Study NCT04413370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dry eye diagnostic test
Description: The artificial intelligent dry eye screening platform
Study NCT02346929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound guide
Description: Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
Study NCT00878293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
Study NCT00878293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS Continus®
Description: 60 mg, capsule, once daily
Study NCT00878293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid formulation and capsule, once daily
Study NCT04409522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
Study NCT04409522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The usual treatment
Description: Participants in this group will receive the usual treatment of COVID-19
Study NCT04409522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The usual treatment
Description: Participants in this group will receive the usual treatment of COVID-19
Study NCT04961632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of >30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
Study NCT04961632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
Study NCT02800447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natulan
Description: Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1\~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1\~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1\~14
Study NCT02800447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD
Description: Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
Study NCT04021225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ectoin® Allergy Eye Drops 2%
Description: A one-time application of 1-2 drops in the more affected eye will be investigated.
Study NCT04021225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ectoin® Eye Spray Colloidal
Description: A one-time application of 1-2 drops in the more affected eye will be investigated.
Study NCT04021225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tears Again® eye spray
Description: A one-time application of 1-2 drops in the more affected eye will be investigated.
Study NCT02754336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cogmed Robomemo, working memory training
Study NCT02754336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Othmer, neurofeedback
Study NCT02462343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: walk tests
Study NCT00264563 — intervention group
Intervention type: BEHAVIORAL
Intervention: Increasing the level of awareness to Iatrogenesis
Description: Increasing the level of awareness to Iatrogenesis
Study NCT00264563 — intervention group
Intervention type: BEHAVIORAL
Intervention: Increasing awareness .
Description: Increasing awareness to Iatrogenesis and active daily recordings
Study NCT02361398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the EIT guide the individualized PEEP Setting
Description: the EIT guide the individualized PEEP Setting in the EIT group
Study NCT03470545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules
Study NCT03470545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral capsule
Study NCT01309477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Sustained-release Capsules (ADVAGRAF)
Description: Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
Study NCT01339962 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional (retrospective chart reviews)
Study NCT01144962 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.
Description: Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
Study NCT01144962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.
Description: Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
Study NCT00507156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard primary PCI
Description: Acute re-opening of the occluded coronary artery
Study NCT00507156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical postconditioning
Description: Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
Study NCT04351945 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
Study NCT03157908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareConekta
Description: CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
Study NCT01355978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Open Ventilation System
Description: Noninvasive ventilation system
Study NCT01061190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: oral application of 160 mg Propranolol for 30 days
Study NCT01061190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: oral application of 160 mg Propranolol for 30 days
Study NCT03230045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Description: Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
Study NCT03230045 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: no treatment
Description: electrodes are attached, but no stimulation is given
Study NCT03704506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxil capsule simulator
Description: amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
Study NCT02249507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
Study NCT05040945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional corticotomy
Description: Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with traditional corticotomy will be applied.
Study NCT05040945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless corticotomy
Description: Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with flapless corticotomy will be applied.
Study NCT02835092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Take Shape For Life Program
Description: The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 \& 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
Study NCT02835092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medifast Direct Program
Description: The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 \& 2 \& 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
Study NCT02835092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed Control
Description: The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
Study NCT04442347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-810
Description: ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) mRNA formulated in a lipid nanoparticle (LNP) under development.
Study NCT04442347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for this study is 0.9% sterile saline.
Study NCT00565838 — intervention group
Intervention type: PROCEDURE
Intervention: AFS and TVT
Description: Autologous Fascial Sling and Tension- Free Vaginal Tape
Study NCT02547441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001 (Omiganan)
Description: Topical gel
Study NCT02547441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Gel
Study NCT01427049 — intervention group
Intervention type: DEVICE
Intervention: renal denervation
Description: percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
Study NCT02181907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UH-AC 62 XX tablet
Study NCT02181907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UH-AC 62 XX tablet
Study NCT02181907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UH-AC 62 XX capsule
Study NCT02181907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UH-AC 62 XX capsule
Study NCT01601912 — intervention group
Intervention type: DRUG
Intervention: Atomoxetine
Description: 40 mg, 1 application
Study NCT01601912 — intervention group
Intervention type: DRUG
Intervention: Citalopram
Description: 20 mg, 1 application